Nutraceutical major British Biologicals has now lined up two nutritional products Promaxe and Nutrizen from its Criticare Division to address the conditions like burns, post surgery and multiple trauma which require adequate nutrient and metabolic support to control pain and uneasiness.
The state of stress on the body expends large amounts of energy to heal inflammation, support immune function and tissue repair. Comprehending the needs for protein rich supplements providing high calories for trauma patients recovering from major injuries, British Biologicals research team came out with the two products, which are the revenue generators of the future.
While Promaxe is enriched with glutamine to meet the needs of patients including burns, infections like HIV and cancer, Nutrizen is a nutritional supplement that provides adequate calories, proteins, vitamins and zinc needed for rapid wound healing and allergy due to nutritional deficiencies, stated VS Reddy, chairman and managing director, British Biologicals.
The two new launches takes the total number of products of the company to 12. “From our range which cover general health with ‘B Protein’, women’s health with ‘Pro PL and ‘Meno Pro’, child health with ‘Kids Pro’ diabetes with ‘D Pro’, cholesterol management with Colred, Liver with ‘Hepa Pro’, weight management with Medislim and Pulmonary distress with Pulmocare, and Pulmoplus, we have found that Hepa Pro, Pulmocare, and Pulmoplus are the fastest growing in the range. In fact in fiscal 2010-11, B Protein and D Protein chipped in 65 per cent to the company’s revenues of Rs.400 crore. In the last 3 years, the company registered an annual growth rate of 22 percent,” he added.
The company also exports to 16 countries including South East Asia, Africa, Middle East, Russia and the USA. However over 95 per cent of its revenues are from the export market.
As a dedicated nutraceutical major, British Biologicals holds a leadership status in a market valued at Rs.400 crore. In order keep the tempo of new products and growth, it has slated a Rs.150 crore investment for a Greenfield production plant constructed according to US FDA regulations at Jigani Industrial Area, Bangalore on a four acre lot. The plant would span over an area of 1.5 lakh sq.ft, out of which 25,000 sq. ft would be a dedicated area for R&D and quality control labs. The funds would be raised through internal accruals.
Future areas of focus would be neurology and orthopaedic segments which require a nutritional supplement to address the systemic inflammatory response syndrome.
“Going by the promising prospects in the market, we would tap every opportunity for growth. Therefore we are looking to increase manpower strength, devise strategies to augment market share, expand product offering to make the right moves for global forays,” stated the British Biologicals chief.
India nutraceutical market is estimated to be Rs.4,000 crore and players in the space include Abbot, Pfizer, Nestle Nutrition, Novartis, Zydus Cadila, Amway, Pristine and Satva Foods.